Immunosuppressive receptor LILRB1 acts as a potential regulator in hepatocellular carcinoma by integrating with SHP1
Immunosuppressive receptor LILRB1 acts as a potential regulator in hepatocellular carcinoma by integrating with SHP1
复制标题
免疫抑制受体 LILRB1 通过与 SHP1 整合作为肝细胞癌的潜在调节因子
DOI：
10.3233/cbm-190940
复制
发表时间：
2020-01-01
影响因子：
3.1
通讯作者：
Gou, Xingchun
中科院分区：
文献类型：
--
作者：
Cheng, Jianghong;Luan, Jing;Gou, Xingchun
背景技术背景：免疫抑制受体LILRB 1通过细胞内基于酪氨酸的抑制基序转导免疫抑制信号来调节肿瘤进展。目的：探讨LILRB 1与肝癌的关系。方法：采用免疫印迹法和qRT-PCR技术检测LILRB 1在肝癌细胞中的表达水平。免疫组化染色检测组织芯片中LILRB 1阳性细胞。采用基因表达谱交互分析（Gene Expression Profiling Interactive Analysis，GEPIA）和Oncomine数据库分析LILRB 1、SHP 1和SHP 2与肝癌细胞存活率的关系。在临床上，LILRB 1在75对癌旁组织中的49对（65%）显著高于配对HCC样本。在组织芯片中，75例HCC受试者中有48例（64%）显示低水平的LILRB 1，而在配对的相邻组织中有25例（33%）。Oncomine数据库和GEPIA分析证实LILRB 1在HCC中低于正常组织。此外，低LILRB 1水平与HCC患者的临床病理特征和无病生存期显著相关，但与总生存期无关。结论：LILRB 1可能通过整合SHP 1而发挥抗肿瘤作用，提示LILRB 1可能参与了肝癌的病理过程。
BACKGROUND: Immunosuppressive receptor LILRB1 regulates tumors progression by transducing immune inhibitory signals via intracellular immunoreceptor tyrosine-based inhibitory motifs. However, its role in Hepatocellular Carcinoma (HCC) remains vague.OBJECTIVE: This study is aimed to disclose the association between LILRB1 and HCC.METHODS: Immunoblotting and qRT-PCR were employed to evaluate the level of LILRB1 in hepatocarcinoma cells. LILRB1positive cells in tissue array were measured using immunohistochemistry staining. The relation among LILRB1, SHP1 and SHP2 and survival rates were analyzed using Gene Expression Profiling Interactive Analysis (GEPIA) and Oncomine database.RESULTS: LILRB1 was robustly reduced in hepatocarcinoma cells compared to normal cells. Clinically, LILRB1 was significantly higher in 49 of 75 (65%) paired paracarcinoma tissues than that in paired HCC samples. 48 of 75 (64%) HCC subjects in tissue microarray showed low level of LILRB1, compared to 25 of 75 (33%) in paired-adjacent tissues. Oncomine database and GEPIA analysis confirmed that LILRB1 was lower in HCC than normal tissues. Additionally, lowLILRB1 had a significant association with clinicopathological characteristics and Disease Free Survival, but no association with Overall Survival in HCC patients. Mechanismly, positive correlation between LILRB1 and SHP1, but not SHP2 was observed in HCC.CONCLUSIONS: LILRB1 possibly plays an antitumor effect in hepatocarcinoma cells by integrating SHP1, providing evidence that LILRB1 might be involved in the pathologic progression of HCC.